SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials A strategic partnership among SynuSight Biotech, ABLi Therapeutics, and XingImaging aims to enhance clinical trials of risvodetinib through advanced imaging techniques for Parkinson's disease.

SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials #United_States #New_Haven #XingImaging #SynuSight #ABLi_Therapeutics